Ellence (Bladder Cancer) - Analysis and Forecasts to 2020

Date: October 1, 2011
Pages: 24
Price:
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E295709498AEN
Leaflet:

Download PDF Leaflet

Ellence (Bladder Cancer) - Analysis and Forecasts to 2020
Ellence (Bladder Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Ellence (Bladder Cancer) - Analysis and Forecasts to 2020” provides Ellence EU sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2012). The report also includes information on Bladder Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Summary
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Ellence including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Ellence including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Global sales forecasts for 2002-2012 for Ellence

Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Bladder Cancer Market
2.2 Bladder Cancer Disease
2.3 GlobalData Report Guidance

3 BLADDER CANCER DISEASE: MARKET CHARACTERISTICS

3.1 Bladder Cancer Disease Market
3.2 Bladder Cancer Disease Market Forecasts
3.3 Drivers for the Bladder Cancer Disease Market
  3.3.1 High Prevalence
  3.3.2 High Incidence
  3.3.3 High Survival Rate
  3.3.4 High lifetime costs

4 TNM CLASSIFICATION OF BLADDER CANCER

4.1 American Urological Association

5 ELLENCE

5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Approval History of Ellence
5.5 Contraindications
5.6 Factors Impacting Sales
  5.6.1 Bladder Cancer Market Characteristics
  5.6.2 Moderate Efficacy
  5.6.3 Poor Safety Profile
  5.6.4 Competition
5.7 Drug Risk Benefit Score (DRB)
  5.7.1 Efficacy
  5.7.2 Safety
  5.7.3 Compliance
  5.7.4 Dosing Convenience
5.8 Sales forecast
  5.8.1 Target Patient Pool of Ellence
  5.8.2 Dosing of Ellence
  5.8.3 Market Penetration
  5.8.4 Annual Cost of Therapy
  5.8.5 Sales Projections of Ellence

6 BLADDER CANCER MARKET: APPENDIX

6.1 Market Definitions
6.2 List of Abberiviations
6.3 Research Methodology
  6.3.1 Coverage
  6.3.2 Secondary Research
  6.3.3 Forecasting
  6.3.4 Number of Patients Approved to take the Drug
  6.3.5 Net Penetration of Drug
  6.3.6 Net Annual Dosing
  6.3.7 Annual Cost of Therapy
  6.3.8 Primary Research
  6.3.9 Expert Panels
6.4 Contact Us
6.5 Disclaimer
6.6 Sources

LIST OF TABLES

Table 1: Bladder Cancer Incidences & Mortality
Table 2: Bladder Cancer, Global, Market Forecasts ($bn), 2009–2020
Table 3: Drug Approval , Expiry and Indications
Table 4: Drug Risk Benefit Score
Table 5: Dosage

LIST OF FIGURES

Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers
Figure 2: Fatality = [(%Distribution of Incidence) –(% Distribution Mortality )] of Top 20 Cancers
Figure 3: Percentage share of risk factors in “Developed Countries”
Figure 4: Percentage share of risk factors in “Developing Countries”
Figure 5: Smoking Consumption Curve, US,1960-2006
Figure 6: Bladder Cancer, Global, Market Size Forecasts ( $bn) , 2009-2020
Figure 7: Oncology, Worldwide, Estimated Incidence 2008-2030
Figure 8: Bladder Cancer, Worldwide, Estimated Incidence 2008-2030
Figure 9: Broad Classification of Bladder Cancer
Figure 10: Classification of NMI Bladder Cancer
Figure 11: Detailed TNM Classifications
Figure 12: Classification of NMI Bladder Cancer
Figure 13: Ellence Drug Model Diagram
Figure 14: Bladder Cancer, EU, Sales Forecasts for Ellence ( $m), 2002-2012

Ask Your Question

Ellence (Bladder Cancer) - Analysis and Forecasts to 2020
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: